<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796913</url>
  </required_header>
  <id_info>
    <org_study_id>RISG2</org_study_id>
    <nct_id>NCT00796913</nct_id>
  </id_info>
  <brief_title>Remission Induction and Sustenance in Graves' Disease 2</brief_title>
  <official_title>Prospective Randomized Study of Therapy Withdrawal vs Continued Low Dose Medical Therapy in Patients With Graves' Disease Entering Remission During ATD Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ATD therapy for Graves' disease is one of the commonly used options for therapy of the
      hyperthyroidism. The investigators study how to optimally keep patients in remission.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A detailed description of patients entering the initial observational phase of the study
      (RISG1) has been published:

      Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen
      SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy
      in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study.
      J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 7, 2008</start_date>
  <completion_date type="Actual">May 15, 2015</completion_date>
  <primary_completion_date type="Actual">May 15, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse of hyperthyroidism</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reoccurrence of TSH-receptor autoimmunity</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Graves Disease</condition>
  <condition>Hyperthyroidism</condition>
  <arm_group>
    <arm_group_label>Stop of medication after remission</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After enetering remission patients are randomised to continue low dose medication or to stop medication: Overview of study described in:
Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medication for 2 yrs after remission</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>See Laurberg P, Nygaard B, Andersen S, Carlé A, Karmisholt J, Krejbjerg A, Pedersen IB, Andersen SL. Association between TSH-Receptor Autoimmunity, Hyperthyroidism, Goitre, and Orbitopathy in 208 Patients Included in the Remission Induction and Sustenance in Graves' Disease Study. J Thyroid Res. 2014;2014:165487. doi: 10.1155/2014/165487.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Se-yeast 200 Microgr/day + arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional arm where patients have been taking Se supplements during RISG1 therapy, and for 2 years after ATD withdrawal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stop medication</intervention_name>
    <description>Stop medication Stop medication + se supplement</description>
    <arm_group_label>Se-yeast 200 Microgr/day + arm A</arm_group_label>
    <arm_group_label>Stop of medication after remission</arm_group_label>
    <other_name>stop medication + se supplement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Graves hyperthyroidism in remission after ATD

        Exclusion Criteria:

          -  Age &lt; 18, severe concomitant disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jesper S Karmisholt, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital</affiliation>
  </overall_official>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 21, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Jesper Scott Karmisholt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

